Cargando…

Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy

Chronic myeloid leukemia (CML) is a blood cancer characterized by dysregulated production of maturing myeloid cells driven by the product of the Philadelphia chromosome, the BCR-ABL1 tyrosine kinase. Tyrosine kinase inhibitors (TKIs) have proved effective in treating CML, but there is still a cohort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodriguez, Jonathan, Iniguez, Abdon, Jena, Nilamani, Tata, Prasanthi, Liu, Zhong-Ying, Lander, Arthur D, Lowengrub, John, Van Etten, Richard A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2023
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212564/ https://www.ncbi.nlm.nih.gov/pubmed/37115622 http://dx.doi.org/10.7554/eLife.84149

Ejemplares similares

Varying effects of tyrosine kinase inhibitors on platelet function—A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
por: Deb, Suryyani, et al.
Publicado: (2019)

Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes
por: Ruiz-Vega, Rolando, et al.
Publicado: (2020)

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
por: Katayama, Yuki, et al.
Publicado: (2022)

Suppression of tumor immune microenvironment via microRNA‐1 after epidermal growth factor receptor‐tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma
por: Kawana, Sachiko, et al.
Publicado: (2020)

The impact of Rhodiola rosea on biomarkers of diabetes, inflammation, and microbiota in a leptin receptor-knockout mouse model
por: Jafari, Mahtab, et al.
Publicado: (2022)

Exosome‐transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma
por: Li, Qiming, et al.
Publicado: (2020)

EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression
por: Lin, Zong-Shin, et al.
Publicado: (2023)

BCR‐ABL1 transcript levels at 4 weeks have prognostic significance for time‐specific responses and for predicting survival in chronic‐phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors
por: Song, Hye‐young, et al.
Publicado: (2018)

When oncogenes do not cause cancer
por: Shiu, Jessica, et al.
Publicado: (2021)

Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome
por: Secombe, Kate R., et al.
Publicado: (2020)

An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression
por: Ryu, Jaewook, et al.
Publicado: (2018)

Novel ATP‐competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
por: Yamaji, Masayuki, et al.
Publicado: (2017)

Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
por: Martino, Julieta, et al.
Publicado: (2023)

Molecular and epigenetic alterations in normal and malignant myelopoiesis in human leukemia 60 (HL60) promyelocytic cell line model
por: Basu, Jhinuk, et al.
Publicado: (2023)

MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation
por: Arai, Seiji, et al.
Publicado: (2020)

Correction: Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
por: Martino, Julieta, et al.
Publicado: (2023)

Trained innate immunity, long-lasting epigenetic modulation, and skewed myelopoiesis by heme
por: Jentho, Elisa, et al.
Publicado: (2021)

Thoracoscopic lobectomy following neoadjuvant tyrosine kinase inhibitor treatment
por: Chudgar, Neel P., et al.
Publicado: (2021)

TAE226, a dual inhibitor of focal adhesion kinase and insulin‐like growth factor‐I receptor, is effective for Ewing sarcoma
por: Moritake, Hiroshi, et al.
Publicado: (2019)

PU.1 is required to restrain myelopoiesis during chronic inflammatory stress
por: Chavez, James S., et al.
Publicado: (2023)

The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma cells without a t(11;14) translocation
por: Sundaramoorthy, Pasupathi, et al.
Publicado: (2018)

Reducing tumor invasiveness by ramucirumab and TGF‐β receptor kinase inhibitor in a diffuse‐type gastric cancer patient‐derived cell model
por: Lee, Song‐Yi, et al.
Publicado: (2021)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Myelopoiesis and Myeloid Leukaemogenesis in the Zebrafish
por: Forrester, A. Michael, et al.
Publicado: (2012)

Focal adhesion kinase activation limits efficacy of Dasatinib in c‐Myc driven hepatocellular carcinoma
por: Liu, Xianqiong, et al.
Publicado: (2018)

The impact of dietary isoflavonoids on malignant brain tumors
por: Sehm, Tina, et al.
Publicado: (2014)

Genetic alterations associated with multiple primary malignancies
por: Nyqvist, Jenny, et al.
Publicado: (2021)

Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin
por: Zhang, Yiming, et al.
Publicado: (2016)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

Expression and ERG regulation of PIM kinases in prostate cancer
por: Eerola, Sini K., et al.
Publicado: (2021)

Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors
por: Zhang, Lei, et al.
Publicado: (2022)

MASTL: A novel therapeutic target for Cancer Malignancy
por: Fatima, Iram, et al.
Publicado: (2020)

Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAF(V600E) oncoprotein kinase
por: van Veen, J Edward, et al.
Publicado: (2019)

Corrupted adipose tissue endogenous myelopoiesis initiates diet-induced metabolic disease
por: Luche, Elodie, et al.
Publicado: (2017)

Relevance of treatment‐free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2021)

Mutant SF3B1 promotes malignancy in PDAC
por: Simmler, Patrik, et al.
Publicado: (2023)

Quercetin suppresses lung cancer growth by targeting Aurora B kinase
por: Xingyu, Zhu, et al.
Publicado: (2016)

Dynamics of human protein kinase Aurora A linked to drug selectivity
por: Pitsawong, Warintra, et al.
Publicado: (2018)

One reporter for in-cell activity profiling of majority of protein kinase oncogenes
por: Gudernova, Iva, et al.
Publicado: (2017)

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
por: Campbell, Robert, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_net0d8qekbusl0ut0ct9ppd9b1